Large CapHealthcare

MRNA — Moderna, Inc.

Biotechnology · Founded 2010 · Cambridge, Massachusetts · CEO: Stephane Bancel

Moderna is a biotechnology company that pioneered messenger RNA (mRNA) therapeutics and vaccines. Its COVID-19 vaccine (Spikevax) was authorized in December 2020 and became one of the best-selling pharmaceutical products in history. Post-pandemic, Moderna is deploying its mRNA platform to develop vaccines for respiratory viruses (RSV, flu-COVID combination), personalized cancer vaccines (with Merck), and rare diseases. The company is in a critical transition from COVID dependence to a diversified pipeline.

How Moderna, Inc. Makes Money

Spikevax COVID-19 vaccine sales to governments and commercial channels

mRESVIA RSV vaccine revenue from newly approved respiratory vaccine

U.S. government advanced purchase agreements and pandemic preparedness contracts

Future pipeline revenue expected from personalized cancer vaccine (mRNA-4157) and other programs

Key Metrics Investors Watch

COVID vaccine revenue and market share vs. Pfizer/BioNTech
RSV vaccine (mRESVIA) uptake in its first commercial season
Pipeline advancement milestones in flu-COVID combination, cancer vaccine (mRNA-4157)
Cash runway to support pipeline without vaccine revenue
Cost reduction per dose from manufacturing improvements

Competitive Advantages

mRNA platform technology enables rapid vaccine design against novel pathogens
Spikevax demonstrated mRNA vaccine safety and efficacy at unprecedented scale
Partnership with Merck on personalized cancer vaccine (PCV) leverages both companies' strengths
Manufacturing scale-up expertise and global supply chain established during COVID

Key Risks

Revenue is highly concentrated in COVID vaccine, which is declining as pandemic urgency fades
Non-COVID pipeline products have not yet generated material revenue
Competition from Pfizer/BioNTech in mRNA vaccines and from traditional vaccine makers in RSV/flu
R&D spending is very high relative to current revenue, creating cash burn pressure

Dividend & Capital Return

Moderna does not pay a dividend. The company is investing heavily in pipeline development and manufacturing infrastructure to diversify beyond COVID vaccines.

I Document Every Trade — Even the Losses

Options record: 1W-8L. Net worth: 100% GSE preferred. Get the unfiltered updates.

Unsubscribe anytime. I respect your inbox more than Congress respects property rights.

Frequently Asked Questions

What is Moderna's mRNA platform?

Moderna's mRNA platform delivers genetic instructions that teach the body's cells to produce a protein, triggering an immune response. The same manufacturing technology can be rapidly adapted to different targets, enabling rapid vaccine development against new pathogens or cancer neoantigens. This is educational content, not financial advice.

Is Moderna a good investment after COVID?

Post-pandemic, Moderna is a high-risk/high-reward investment dependent on whether its pipeline beyond COVID vaccines (RSV, flu combination, cancer vaccine) succeeds commercially. Its mRNA platform is genuinely differentiated but pipeline execution risk is high. This is educational content, not financial advice.

What is Moderna's personalized cancer vaccine?

Moderna, in partnership with Merck, is developing mRNA-4157 (V940), a personalized cancer vaccine that is customized for each patient based on the neoantigens unique to their tumor. Early Phase 2 data in melanoma showed promising results in combination with Keytruda. This is educational content, not financial advice.

Does Moderna pay a dividend?

No, Moderna does not pay a dividend. The company retains cash to fund its extensive clinical pipeline and manufacturing investments as it attempts to diversify revenue beyond COVID vaccines. This is educational content, not financial advice.

How does Moderna compare to Pfizer/BioNTech?

Both use mRNA technology for COVID vaccines. Pfizer/BioNTech co-developed Comirnaty, which captured more market share in many markets. Moderna's Spikevax used a higher dose formulation and full mRNA sequence. Both compete in RSV and combination flu-COVID vaccines. This is educational content, not financial advice.

Related Stocks

ABBV

AbbVie Inc.

Healthcare

AbbVie is a global biopharmaceutical company focused on immunology, oncology, neuroscience, and eye care. Spun off from Abbott Laboratories in 2013, AbbVie is best known for Humira (the world's best-selling drug of all time) and its successor drugs Skyrizi and Rinvoq.

PFE

Pfizer Inc.

Healthcare

Pfizer is one of the world's largest pharmaceutical companies, with a diversified portfolio spanning oncology, immunology, rare diseases, vaccines, and hospital medicines. The company became globally prominent during the COVID-19 pandemic through its co-developed mRNA vaccine (Comirnaty) with BioNTech and antiviral pill Paxlovid. Post-pandemic, Pfizer has focused on restoring growth through acquisitions including Seagen (oncology) and deploying its substantial cash reserves. The company faces significant patent cliffs on several major drugs in the late 2020s.

GILD

Gilead Sciences, Inc.

Healthcare

Gilead Sciences is a biopharmaceutical company specializing in antiviral drugs, particularly for HIV, hepatitis, and COVID-19. Its HIV franchise (Biktarvy, Descovy, Genvoya, Truvada) dominates the global HIV treatment market and generates billions in annual revenue. Gilead's hepatitis C drugs (Harvoni, Sovaldi) effectively cured the disease and transformed the treatment paradigm, though that market has since contracted as the curable population has been treated. Gilead is expanding into oncology through its Kite Pharma (CAR-T cell therapy) platform.

Recommended Resources

Tools & books I actually use and recommend

Interactive Brokers

Low commissions, global market access, and professional-grade tools. This is where I hold my positions.

Open an Account

A Random Walk Down Wall Street

Burton Malkiel's classic case for index investing. The book that convinced millions to stop stock-picking.

View on Amazon

TradingView

Best charting platform out there. Real-time data, screeners, and a community of millions of traders.

Try TradingView

Some links above are affiliate links. I only recommend products I personally use. See my full disclosures.

Keep Exploring

Hub

All Stocks

Browse all 134 stock profiles by sector.

Best Stocks For Beginners

Curated stock picks for new investors by goal.

Financial Glossary

Understand the terms investors use every day.

Stock vs ETF

Individual stocks vs ETFs — which is right for you?

ETF Profiles

Deep dives on 90+ ETFs across every category.

Buying Your First Stock

How to open a brokerage and buy your first share.

Browse All 134 Stock Profiles

Company information is based on publicly available disclosures and widely-known business facts. No specific price, earnings, or real-time market data is included. This is educational content — not investment advice.